Tagworks to present preclinical data demonstrating potential of its Click-to-Release platform to enable safe, tolerable, and potent delivery of therapeutic candidates for solid tumors
Nijmegen, Netherlands and BOSTON – Tagworks Pharmaceuticals BV (“Tagworks”), a precision oncology company using its proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors, today announced two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois.
Poster Presentation Details
Abstract Number: 1794
Title: “Preclinical development of TGW101, a first in class click-cleavable ADC with MMAE against non-internalizing pan-carcinoma marker TAG72”
Session Title: Novel Drug Delivery Technologies
Date and Time: Monday, April 28, 2025, 9:00 a.m. – 12:00 p.m. CDT
Location: Poster Section 23
Presenter: Marc Robillard, Ph.D., Chief Scientific Officer and Co-Founder, Tagworks
Abstract Number: 3486
Title: “Click-to-Release for controlled immune cell activation: tumor-targeted unmasking of an IL-12 prodrug in vivo”
Session Title: Local Treatments, Novel Tools, and Delivery Systems to Manipulate Tumor Immunity
Date and Time: Monday, April 28, 2025, 2:00 – 5:00 p.m. CDT
Location: Poster Section 37
Presenter: Martijn den Brok, Ph.D., Head of Biology, Tagworks
The posters will be made available at www.tagworkspharma.com/publications following the presentations.
About Tagworks Pharmaceuticals
Tagworks Pharmaceuticals is a precision oncology company using its proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors by targeting clinically validated tumor markers that so far have remained out of reach of current therapies. Its lead program, TGW101, is an antibody-drug conjugate (ADC) targeting TAG72, a non-internalizing protein found on the surface of many solid tumor cells. Tagworks is developing a pipeline of novel cancer treatments leveraging its Click-to-Release technology in a range of therapeutics modalities, including ADCs and targeted radiopharmaceuticals. The company is headquartered in the Netherlands with operations in the U.S. For more information, visit us at www.tagworkspharma.com.
Contact
Media and Investors
Deborah Elson/Maeve Conneighton
Argot Partners
(212) 600-1902
tagworks@argotpartners.com
